Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Br J Cancer. 2023 Oct;129(6):1022-1031. doi: 10.1038/s41416-023-02375-y. Epub 2023 Jul 28.
Br J Cancer. 2023.
PMID: 37507543
Free PMC article.
Clinical Trial.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.
Toomey S, et al. Among authors: teiserskiene a.
Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.
Breast Cancer Res. 2017.
PMID: 28750640
Free PMC article.
Clinical Trial.
Item in Clipboard
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Keegan NM, Furney SJ, Walshe JM, Gullo G, Kennedy MJ, Smith D, McCaffrey J, Kelly CM, Egan K, Kerr J, Given M, O'Donovan P, Hernando A, Teiserskiene A, Parker I, Kay E, Farrelly A, Carr A, Calzaferri G, McDermott R, Keane MM, Grogan L, Breathnach O, Morris PG, Toomey S, Hennessy BT.
Keegan NM, et al. Among authors: teiserskiene a.
Cancers (Basel). 2021 Mar 11;13(6):1225. doi: 10.3390/cancers13061225.
Cancers (Basel). 2021.
PMID: 33799597
Free PMC article.
Item in Clipboard
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Eustace AJ, Madden SF, Fay J, Collins DM, Kay EW, Sheehan KM, Furney S, Moran B, Fagan A, Morris PG, Teiserskiene A, Hill AD, Grogan L, Walshe JM, Breathnach O, Power C, Duke D, Egan K, Gallagher WM, O'Donovan N, Crown J, Toomey S, Hennessy BT.
Eustace AJ, et al. Among authors: teiserskiene a.
Breast Cancer Res Treat. 2021 Jun;187(3):635-645. doi: 10.1007/s10549-021-06244-1. Epub 2021 May 13.
Breast Cancer Res Treat. 2021.
PMID: 33983492
Free PMC article.
Item in Clipboard
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, McLoughlin O, Teiserskiene A, Power C, O'Shea AM, Greally M, Morris PG, Duke D, Hill ADK, Hennessy BT.
Dowling GP, et al. Among authors: teiserskiene a.
BMC Cancer. 2024 Jan 17;24(1):91. doi: 10.1186/s12885-024-11851-4.
BMC Cancer. 2024.
PMID: 38233810
Free PMC article.
Item in Clipboard
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.
McDermott RS, Greene J, McCaffrey J, Parker I, Helanova S, Baird AM, Teiserskiene A, Lim M, Matthews H, Deignan O, Feeney J, Thirion PG, Finn SP, Kelly PJ.
McDermott RS, et al. Among authors: teiserskiene a.
Ther Adv Med Oncol. 2021 Sep 6;13:17588359211042691. doi: 10.1177/17588359211042691. eCollection 2021.
Ther Adv Med Oncol. 2021.
PMID: 34512801
Free PMC article.
Item in Clipboard
Mediated oxidation of ascorbic acid on a homologous series of ferrocene-terminated self-assembled monolayers.
Kazakeviciene B, Valincius G, Niaura G, Talaikyte Z, Kazemekaite M, Razumas V, Plausinaitis D, Teiserskiene A, Lisauskas V.
Kazakeviciene B, et al. Among authors: teiserskiene a.
Langmuir. 2007 Apr 24;23(9):4965-71. doi: 10.1021/la0632169. Epub 2007 Mar 23.
Langmuir. 2007.
PMID: 17378593
Item in Clipboard
Cite
Cite